Article

Patent disputes ended over eye vitamins

Rochester, NY—Bausch & Lomb has resolved a pair of patent disputes involving its Ocuvite PreserVision eye vitamins.

Rochester, NY-Bausch & Lomb has resolved a pair of patent disputes involving its Ocuvite PreserVision eye vitamins.

The company, which holds worldwide patent rights to the formula developed by the Age-Related Eye Disease Study (AREDS), settled a lawsuit against Alcon Laboratories Inc. and dismissed a second against Inverness Medical Innovations Inc.

Bausch & Lomb had developed the formula for the vitamins with the National Eye Institute and supplied the tablets for the 10-year AREDS, the results of which were released in October 2001.

The companies announced March 18 that they settled the dispute by creating a cross-licensing deal in which Alcon will sell its product and grant Bausch & Lomb global rights under "one or more" Alcon patents. The terms, which were confidential, were approved by the U.S. Public Health Service, which had granted Bausch & Lomb the license.

"The product has gained significant market share and copycat products appeared thereafter," said Margaret Graham, a Bausch & Lomb spokeswoman.

Doug MacHatton, Alcon's vice president, investor relations and strategic corporate communications, was unavailable for comment.

In the Inverness dispute, Bausch & Lomb alleged in a March 8 lawsuit that Waltham, MA-based Inverness and its subsidiary IVC Industries Inc. manufacture and distribute vitamins that infringe its patent for Ocuvite PreserVision. However, 3 days later, Bausch & Lomb dismissed the lawsuit, saying the companies had provided "a written representation" that neither had infringed the Bausch & Lomb patent.

"This matter was able to be clarified quickly as a result of Inverness' thorough internal review and prompt, direct communication," Bausch & Lomb said in its press release.

"Inverness provided information to Bausch & Lomb after the lawsuit was filed and, on the basis of that information, the action was withdrawn," Graham added.

Doug Guarino, director of corporate communications for Inverness, did not return a phone call seeking comment.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.